Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Singapore medical journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.11622/smedj.2017082PMID 28848988PMCID PMC5563527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationships between Prostatic Volume and Intravesical Prostatic Protrusion on Transabdominal Ultrasound and Benign Prostatic Obstruction in Patients with Lower Urinary Tract Symptoms.

  2015cited by this paper
• Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.

  2014cited by this paper
• Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients.

  2014cited by this paper
• The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

  2013cited by this paper
• Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction.

  2013cited by this paper
• PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS

  2013cited by this paper
• Serenoa repens for benign prostatic hyperplasia.

  2012cited by this paper
• The prevalence of lower urinary tract symptoms and treatment-seeking behaviour in males over 40 years in Singapore: a community-based study

  2012cited by this paper
• Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

  2011cited by this paper
• Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction

  2010cited by this paper
• The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

  2010cited by this paper
• Staging of benign prostate hyperplasia is helpful in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia.

  2010cited by this paper
• Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment

  2010cited by this paper
• Effect of dutasteride on the risk of prostate cancer.

  2010cited by this paper
• The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

  2008cited by this paper
• Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

  2007cited by this paper
• Alpha blockers for the treatment of benign prostatic hyperplasia.

  2007cited by this paper
• A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system.

  2007cited by this paper
• Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic‐specific antigen in the evaluation of bladder outlet obstruction (Author's Reply)

  2007cited by this paper
• Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

  2006cited by this paper
• A population study of nocturia in Singapore

  2006cited by this paper
• Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.

  2006cited by this paper
• Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

  2006cited by this paper
• Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases.

  2005cited by this paper
• Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries

  2005cited by this paper
• Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1‐adrenoceptor antagonists

  2005cited by this paper
• Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

  2004cited by this paper
• State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

  2004cited by this paper
• The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

  2003cited by this paper
• Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

  2003cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• Correlation of intravesical prostatic protrusion with bladder outlet obstruction

  2003cited by this paper
• Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention.

  2003cited by this paper
• Effects of bladder volume on transabdominal ultrasound measurements of intravesical prostatic protrusion and volume

  2002cited by this paper
• The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society

  2002cited by this paper
• Pygeum africanum for benign prostatic hyperplasia.

  1998cited by this paper
• A community based study of prostatic symptoms in Singapore.

  1997cited by this paper
• Evidence for atrophy and apoptosis in the prostates of men given finasteride.

  1996cited by this paper
• Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.

  1996cited by this paper
• Current assessment and proposed staging of patients with benign prostatic hyperplasia.

  1995cited by this paper
• Normal histology of the prostate.

  1988cited by this paper
• The development of human benign prostatic hyperplasia with age.

  1984cited by this paper
• The natural history of untreated "prostatism".

  1981cited by this paper

• Coexistence of Nocturia and Frailty and Its Effect on Polypharmacy in Community-Dwelling Older Adults

  2025cites this paper
• Traitement non interventionnel des symptômes du bas appareil urinaire liés à l’hyperplasie bénigne de prostate : recommandations de bonne pratique clinique du Comité des troubles mictionnels de l’homme

  2025cites this paper
• Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

  2025cites this paper
• Surgical treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: an analysis and meta-synthesis of available guidelines

  2025cites this paper
• European Academy of Neurology (EAN)/European Federation of Autonomic Societies (EFAS)/International Neuro‐Urology Society (INUS) Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines)

  2025cites this paper
• Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan’s public healthcare system

  2024cites this paper
• Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription

  2024influential citation
• Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

  2023cites this paper
• Bushen Tongluo formula ameliorated testosterone propionate-induced benign prostatic hyperplasia in rats.

  2023cites this paper
• Pharmacist-led benign prostatic hyperplasia medication management to an optimal goal in the ambulatory care settings: A longitudinal study

  2023cites this paper
• A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia

  2022cites this paper
• The Correlation of Prostate Volume with Uroflowmetry and International Prostatic Symptoms Score (IPSS) on Patient with Benign Prostatic Hyperplasia without Urinary Retention

  2021cites this paper
• Benign Prostatic Hyperplasia (BPH): Perennial Plague of the Prostate

  2021influential citation
• Comparison Between Minimally Invasive Simple Prostatectomy and Open Simple Prostatectomy for Large Prostates: A Systematic Review and Meta-Analysis of Comparative Trials

  2019cites this paper
• Kangquan Recipe Regulates the Expression of BAMBI Protein via the TGF-β/Smad Signaling Pathway to Inhibit Benign Prostatic Hyperplasia in Rats

  2019cites this paper
• Prospective validation of a novel visual analogue uroflowmetry score (VAUS) in 1000 men with lower urinary tract symptoms (LUTS)

  2019cites this paper
• What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?

  2019cites this paper
• Assessment of Lipid Profile of Testosterone and Estradiol induced Benign Prostatic Hyperplasia in Adult Male Rats on Administration of Vernonia amygdalina *1Ugwu

  2019cites this paper
• A Classic Herbal Formula Danggui Beimu Kushen Wan for Chronic Prostatitis: From Traditional Knowledge to Scientific Exploration

  2018cites this paper